Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer

Launched by EASTERN HEPATOBILIARY SURGERY HOSPITAL · Jan 13, 2009

Keywords

ClinConnect Summary

The recurrence and metastasis of primary liver cancer (PLC) have always been a tough problem for surgeons. Gu Hong-guang reported the five years recurrence rate in PLC subjects reached 75\~100%, among which 60% were discovered within three years after surgeries, with the peak appearing at 18\~24 months. According to a report delivered by Zhong-Shan Hospital, the recurrence rate of small HCC was 40%, and that of large HCC was 1.9 times of small HCC. Chen Han agreed that the recurrence rate in 1\~2 years reached 71.6%, while in 2\~11 years was 28.4%. With the rapid development of iconography ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 20\~60 years old;
• • 2. diagnosed HCC pathologically, and confirmed recurrent HCC through ultrasonic B, CT, MRI or DSA test;
• • 3. has a good condition in vital organs such as heart, lung, and kidney;
• • 4. has a good liver function: Child A level, or nearly A level after hepatoprotection treatment;
• • 5. solitary small cancer focus (diameter \<5cm), or the number of recurrent HCC focus is no more than three and all of them grow in the same lobe of liver;
• • 6. without jaundice (not including jaundice in the bile ducts), without ascites or extensive metastasis outside the liver;
• • 7. without invasion to portal vein.
• Exclusion Criteria:
• • 1. subjects refuse to participate in this study;
• • 2. subjects cannot be followed up regularly;
• • 3. subjects with severe heart, lung, kidney diseases;
• • 4. subjects with liver CP level B or C, and serum creatinine ≥2×ULN;
• • 5. subjects with severe bone marrow depression, such as neutrophil counting is lower than 1.5 × 109.